<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Provision</title>
	<atom:link href="http://www.tapanray.in/tag/provision/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Provision for Compulsory Licensing (CL) in India – some issues still need to be addressed.</title>
		<link>http://www.tapanray.in/provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed</link>
		<comments>http://www.tapanray.in/provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed/#comments</comments>
		<pubDate>Thu, 05 Nov 2009 02:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[84]]></category>
		<category><![CDATA[87]]></category>
		<category><![CDATA[92]]></category>
		<category><![CDATA[92A]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[addressed]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Provision]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sections]]></category>
		<category><![CDATA[still]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=736</guid>
		<description><![CDATA[Patent law systems provide for a provision for granting of compulsory licenses in a number of circumstances. Article 5A(2) of The Paris Convention, 1883 indicates that each contracting State may take legislative measures for the grant of compulsory licenses and &#8230; <a href="http://www.tapanray.in/provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will the ‘Bayer–Cipla case’ now put the ‘Bolar Provision’ under judicial scrutiny?</title>
		<link>http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny</link>
		<comments>http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/#comments</comments>
		<pubDate>Thu, 22 Oct 2009 01:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Bayer–Cipla]]></category>
		<category><![CDATA[Bolar]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[judicial]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[now]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Provision]]></category>
		<category><![CDATA[put]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[under]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=748</guid>
		<description><![CDATA[To enable the domestic pharmaceutical industry gaining a critical mass and cater to the pressing healthcare needs of the nation, in 1970 product patent act was abolished by the government of India. This immensely helped the domestic companies to launch &#8230; <a href="http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
